Exact Sciences Corporation - Market Research Report

1. Company Overview

Company Name:

Exact Sciences Corporation

Mission:

Exact Sciences is dedicated to providing science-backed solutions, patient-focused insights, and a human-first approach to cancer detection and treatment. Their purpose is to help eradicate cancer by preventing it, detecting it earlier, and guiding personalized treatment.

Founding Details:

• Founded: 1995

• Initial Public Offering: February 2001

• Founder: Stan Lapidus

Key People:

• Kevin Conroy: Chairman and CEO

• Aaron Bloomer: Executive Vice President, Finance

• Sarah Condella: Executive Vice President, Human Resources

• Brian Baranick: Executive Vice President, General Manager, Precision Oncology

• Jake Orville: Executive Vice President, General Manager, Screening

• Dirk Zimmermann: General Manager, International

• Ana Hooker: Chief Laboratory Officer

• Veronica Descotte: Senior Vice President, Chief Strategy Officer

• Nassar Nizami: Chief Information Officer

• James Herriott: Senior Vice President, General Counsel and Secretary

• Jorge Garces: Chief Science Officer

• Morry Smulevitz: Senior Vice President, Corporate Affairs

Headquarters:

5505 Endeavor Lane, Madison, WI 53719, United States

Number of Employees:

Approximately 6,500+ global employees*

Revenue:

No specific revenue information is available.

Known For:

Exact Sciences is renowned for industry-leading solutions in cancer screening and diagnostic testing with a focus on early detection of colorectal, breast, and liver cancers through innovative products like Cologuard® and Oncotype DX® tests.

2. Products

Overview:

Exact Sciences offers a comprehensive range of cancer screening and diagnostic tests, drawing from their expertise in genomics to provide personalized patient insights.

Key Products and Features:

• Cologuard® Test:

• Type: Colorectal cancer screening

• Sample Type: Stool

• Features: Noninvasive, home-use stool test targeting DNA alterations and presence of blood for colorectal cancer screening in adults 45+ at average risk.

• Oncoguard® Liver Test:

• Type: Surveillance

• Sample Type: Blood

• Features: Helps find common liver cancer types in people with cirrhosis or chronic hepatitis B.

• Riskguard® Test:

• Type: Hereditary cancer risk assessment

• Sample Type: Blood, cheek swab, saliva

• Features: Uncovers hereditary risks for various cancers to inform treatment decisions.

• Oncotype DX® Tests:

• Tests included:

• Oncotype DX Breast DCIS Score® Test

• Oncotype DX Breast Recurrence Score® Test

• Oncotype DX Colon Recurrence Score® Test

• Type: Cancer recurrence risk assessment

• Sample Type: Tissue samples

• Features: Predicts recurrence risk and therapy benefits to guide treatment decisions.

• OncoExTra® Test:

• Type: Genomic therapy selection

• Sample Type: DNA and RNA

• Features: Provides a molecular picture of cancer to aid in therapy decision-making.

In Development:

• Cancerguard™ Test

• CRC Screening Blood Test

• Cologuard Plus™ Test

3. Recent Developments

Recent Developments:

• OncoExTra® Test Launch (2023): This test provides comprehensive DNA- and RNA-based genomic testing to deliver a complete molecular picture of a patient's cancer.

• Riskguard™ hereditary cancer test Launch (2024): New DNA-based hereditary cancer test offering individualized cancer risk assessment via blood or saliva.

New Partnerships:

• Broad Institute Collaboration: An exclusive license agreement to utilize next-generation technology in molecular residual disease research.

• Baylor Scott & White Collaboration: A three-year project to employ multi-cancer early detection testing with real-world clinical insights.

New Products and Features:

• FDA Approval of Cologuard Plus™ Test (2024): Enhancing non-invasive colorectal cancer screening with high sensitivity and specificity.

• Multi-Cancer Early Detection Initiatives: Presented promising data at AACR Special Conference for potential early diagnosis across multiple cancer types.

Additional Insight:

• Exact Sciences continues to explore novel cancer detection methods, highlighted by recent acquisitions to expand their testing capabilities, including Resolution Bioscience and PreventionGenetics.

Note: Every piece of information is sourced from the provided data, with an emphasis on maintaining brevity where specifics such as revenue figures are unavailable.